SCHEMBL139552

SCHEMBL139552

C1CCC(P(C2CCCCC2)C2CCCCC2)CC1.C1CCC(P(C2CCCCC2)C2CCCCC2)CC1.[Pd]

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 1/20 0.32
MGLL Q99685 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6244133 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL3185955 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL1893030 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL27839473 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL2168028 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL379535 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL10548181 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
SCHEMBL3180143 1.00 ALDH1A1 (0.32) ALDH1A1HSD17B10MGLL
Hydrochloric Acid SCHEMBL6224383 0.96 ALDH1A1 (0.30) ALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL4506405 0.96 ALDH1A1 (0.30) ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441745-B2 Processes and compounds RADIUS PHARMACEUTICALS, INC. (US) 2025-10-14 US claimed
EP-3565850-B1 POLYCYCLOOLEFIN POLYMER COMPOSITIONS AS OPTICAL MATERIALS PROMERUS LLC (US) 2025-07-23 EP claimed
CN-120081782-A Preparation method of 2-aminoethyl-3-chloro-5-trifluoromethylpyridine 天津均凯农业科技有限公司 2025-06-03 CN claimed
CN-119930491-A Synthesis method of polysubstituted pyrrolidone 北京化工大学 2025-05-06 CN claimed
CN-119912339-A In the ilast group Process for the preparation of intermediates 浙江天宇药业股份有限公司 2025-05-02 CN claimed
CN-116675672-B Preparation method of antifungal medicine 北京康立生医药技术开发有限公司 2025-04-25 CN claimed
US-12275752-B2 Class of phosphine nitrogen ligand with multiple chiral centers and its synthesis method and application SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2025-04-15 US claimed
US-20250074893-A1 SYNTHESIS OF QUINAZOLINE COMPOUNDS GENENTECH, INC. (US) 2025-03-06 US claimed
WO-2025011547-A1 METHOD FOR OBTAINING ON-DNA AROMATIC COMPOUND VIA SUZUKI COUPLING REACTION AND USE THEREOF 晶泰智药技术(上海)有限公司 2025-01-16 WO claimed
US-12172982-B2 Synthesis of quinazoline compounds GENENTECH, INC. (US) 2024-12-24 US claimed
WO-2004024707-A2 PROCESS FOR PREPARING AMINE TYPE SUBSTITUTED BENZOFURANS ABBOTT LABORATORIES (US) 2004-03-25 WO claimed
US-6566571-B1 Reacting haloaromatics with boron compounds in the presence of a palladium complex DEGUSSA AG (DE) 2003-05-20 US claimed
WO-2003035796-A1 MODIFIED SUZUKI-METHOD FOR POLYMERISATION OF AROMATIC MONOMERS CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2003-05-01 WO claimed
JP-2002541232-A 2002-12-03 JP claimed
EP-0962434-B1 Process for the preparation of aromatic olefins using palladium catalysts containing phosphite ligands DEGUSSA (DE) 2002-11-27 EP claimed
EP-1171406-A1 METHOD OF PRODUCING BIARYLS Degussa AG (DE) 2002-01-16 EP claimed
US-6291383-B1 Process for preparing aromatic olefins in the presence of palladium catalysts comprising phosphite ligands AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) 2001-09-18 US claimed
WO-2000061531-A1 METHOD OF PRODUCING BIARYLS DEGUSSA AG (DE) 2000-10-19 WO claimed
EP-0962434-A1 Process for the preparation of aromatic olefins using palladium catalysts containing phosphite ligands Aventis Research & Technologies GmbH & Co. KG (DE) 1999-12-08 EP claimed
US-4256649-A Synthesis of olefinic oxides from olefin and oxygen AIR PRODUCTS AND CHEMICALS, INC. (US) 1981-03-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12172982-B2 Synthesis of quinazoline compounds COQ8A, SQSTM1, QARS1 ALDH1A1 3460/4885HSD17B10 2691/4885MGLL 4107/4885
US-12441745-B2 Processes and compounds ESR1, ESR2, CYP19A1 ALDH1A1 546/4885HSD17B10 447/4885MGLL 3790/4885
US-12275752-B2 Class of phosphine nitrogen ligand with multiple chiral centers and its synthesis method and application ALK, ATIC, PNISR ALDH1A1 1387/4885HSD17B10 4233/4885MGLL 1252/4885
US-20250074893-A1 SYNTHESIS OF QUINAZOLINE COMPOUNDS COQ8A, SQSTM1, QARS1 ALDH1A1 3460/4885HSD17B10 2691/4885MGLL 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.